Expression of the lung resistance protein (LRP) in primary breast cancer

Anticancer Research

Volumn 19, Issue 6 B, 1999, Pages 5051-5055

  Pohl, Gudrun ^a   Filipits, Martin ^a   Suchomel, Ralf W ^a   Stranzl, Thomas ^a   Depisch, Dieter ^b   Pirker, Robert ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b Wr Neustadt General Hospital   (Austria)

Author keywords

Breast cancer; LRP; Lung resistance; Multidrug resistance; Prognosis; Protein

Indexed keywords

ESTROGEN RECEPTOR; LUNG RESISTANCE PROTEIN; MONOCLONAL ANTIBODY; PROGESTERONE RECEPTOR;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER SURVIVAL; DIAGNOSTIC VALUE; FEMALE; FROZEN SECTION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; SURVIVAL RATE; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 0033382512     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Filipits M, Suchomel RW, Zöchbauer S, Malayeri R, Pirker R: Clinical relevance of drug resistance genes in malignant diseases. Leukemia 10: 10-17, 1996.
2. Merkel DE, Fuqua SAW, Tandon AK, Hill SM, Buzdar AU, McGuire WL: Electrophoretic analysis of 248 clinical breast cancer specimens for P-glycoprotein overexpression or gene amplification. J Clin Oncol 7: 1129-1136, 1989.
3. Schneider J, Bak M, Efferth T, Kaufmann M, Mattern J, Volm M: P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer 60: 815-818, 1989.
4. Wallner J, Depisch D, Hopfner M, Haider K, Spona J, Ludwig H, Pirker R: MDR1 gene expression and prognostic factors in primary breast carcinomas. Eur J Cancer 27: 1352-1355, 1991.
5. Verrelle P, Meissonnier F, Fonck Y, Feillel V, Dionet C, Kwiatkowski F, Plagne R: Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 83: 111-116, 1991.
6. Filipits M, Suchomel RW, Dekan G, Haider K, Valdimarsson G, Depisch D, Pirker R: MRP and MDR1 gene expression in primary breast carcinomas. Clin Cancer Res 2: 1231-1237, 1996.
7. Track BJ, Leonessa F, Clarke R: Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 89: 917-931, 1997.
8. Nooter K, Brutel de la Riviere G, Look MP, van Wingerden KE, Henzen Logmans SC, Scheper RJ, Flens MJ, Klijn JG, Stoter G, Foekens JA: The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer 76: 486-493, 1997.
9. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezetti M, Di Fronzo G, Rilke F, Veronesi U: The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86: 499-504, 1994.
10. Gasparini G, Barbareschi M, Doglioni C, Dalla Palma P, Mauri FA, Boracchi P, Bevilaqua P, Caffo O, Morelli L, Verserio P, Pezzella F, Harris AL: Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1: 189-198, 1995.
11. Bonetti A, Zaninelli M, Leone R, Getto GL, Pelosi G, Biolo S, Menghi A, Manfrin E, Bonetti F, Piubello Q: bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 4: 2331-2336, 1998.
12. Wright C, Cairns J, Cantwell BJ, Cattan AR, Hall AG, Harris AL, Horne CHW: Response to mitoxantrone in advanced breast cancer: correlation with expression of c-erbB-2 protein and glutathione S-transferases. Br J Cancer 65: 271-274, 1992.
13. Aas T, Borresen A-L, Geisler S, Smith-Sorensen B, Johnson H, Varhaug JE, Akslen LA, Lonning PE: Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2: 811-814, 1996.
14. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen TH, van Kalken CK, Slovak ML, de Vries EG, van der Valk P, Meijer CJLM, Pinedo HM: Overexpression of a Mr 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 53; 1475-1479, 1993.
15. Scheffer GL, Wijngaard PLJ, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers, HC, Scheper RJ: The drug resistance-related protein LRP is the human major vault protein. Nat Med 1: 578-582, 1995.
16. Kedersha NL, Rome LH: Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA. J Cell Biol 103: 699-709, 1986.
17. Chugani DC, Rome LH, Kedersha NL: Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex. J Cell Sci 106: 23-29, 1993.
18. Izquierdo MA, van der Zee AGJ, Vermorken JB, Van der Valk P, Belien JA, Giaccone G, Scheffer GL, Flens MJ, Pinedo HM, Kenemans P, Meijer CJLM, De Vries EGE, Scheper RJ: Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 87: 1230-1237, 1995.
19. List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ, Dalton WS: Overexpression of the major vault transporter protein King-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 87: 2464-2469, 1996.
20. Filipits M, Pohl G, Stranzl T, Suchomel RW, Scheper RJ, Jäger U, Geissler K, Lechner K, Pirker R: Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 91: 1508-1513, 1998.
21. Raaijmakers HGP, Izquierdo MAI, Lokhorst HM, De Leeuw C, Behen JAM, Bloem AC, Dekker AW, Scheper RJ, Sonneveld P: Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. Blood 91: 1029-1036, 1998.
22. Izquierdo MA, Scheffer GL, Flens MJ, Giaccone G, Broxterman HJ, Meijer CJ, van der Valk P, Scheper RJ: Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol 148: 877-887, 1996.
23. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
24. Linn SC, Pinedo HM, van Ark-Otte J, Linn SC, Van der Valk P, Hoekman K, Honkoop AH, Vermorken JB, Giaccone G: Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer 71: 787-795, 1997.
25. Abbondanza C, Rossi V, Roscigno A, Gallo L, Belisto A, Piluso G, Medici N, Nigro V, Molinari AM, Moncharmont B, Puca GA: Interaction of vault particles with estrogen receptor in the MCF-7 breast cancer cell. J Cell Biol 141: 1301-1310, 1998.
26. Kickhoefer VA, Rajavel KS, Scheffer GL, Dalton WS, Scheper RJ, Rome LH: Vaults are up-regulated in multidrug-resistant cancer cell lines. J Biol Chem 273; 8971-8974, 1998.